CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) (CRETA)
Evaluation of Response to Clopidogrel in Patients With Essential Thrombocythemia
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm associated with increased platelet production and activation, leading to a high risk of thrombotic complications. Low-dose aspirin is the standard antiplatelet therapy for thrombosis prevention; however, the accelerated platelet turnover characteristic of ET results in rapid recovery of platelet function, making once-daily aspirin insufficient in many patients. Consequently, twice-daily low-dose aspirin is currently recommended to achieve adequate and sustained platelet inhibition.
For patients intolerant to aspirin, clopidogrel 75 mg/day is the approved alternative. Clopidogrel irreversibly inhibits the platelet P2Y12 receptor, but its pharmacodynamic effect is highly variable because it is a prodrug requiring metabolic activation. Studies in non-ET populations have shown that higher clopidogrel doses (150 mg/day) provide stronger and more consistent platelet inhibition without significantly increasing bleeding risk.
Evidence on clopidogrel use in ET is limited, but available data suggest that standard-dose therapy may result in inadequate platelet inhibition, potentially reducing antithrombotic efficacy. Platelet function testing can identify patients with high residual platelet reactivity ("poor responders"), who may benefit from dose escalation. Therefore, in ET patients requiring clopidogrel therapy, assessment of platelet responsiveness may help optimize treatment, ensuring adequate platelet inhibition and potentially improving protection against thrombotic events.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Elena Rossi
- Telefonnummer: +39 0630154206
- E-post: elena.rossi@policlinicogemelli.it
Studiesteder
-
-
-
Pescara, Italia, 65124
- Azienda USL di Pescara - Ospedale Santo Spirito
-
Ta kontakt med:
- Paola Ranalli
- E-post: paola.ranalli@asl.pe.it
-
Hovedetterforsker:
- Paola Ranalli
-
Torino, Italia, 10126
- AOU Citta della Salute e della Scienza di Torino
-
Hovedetterforsker:
- Eloise Beggiato
-
Ta kontakt med:
- Eloise Beggiato
- E-post: ebeggiato@cittadellasalute.to.it
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Consecutive Patients with ET, with an approved indication for clopidogrel therapy (i.e., aspirin intolerance) and a documented good or poor response to the standard 75 mg od dose of clopidogrel at maintenance, as assessed by the standard VN-P2Y12 poinr of care, platelet function test.
At least 50 patients will be enrolled, based on the current records of the participating Centers.
Beskrivelse
Inclusion Criteria:
- Male or female subjects age ≥ 18 years;
- Confirmed diagnosis of ET according to the 2022 WHO classification criteria30;
- Patients treated with clopidogrel 75 mg od as antithrombotic prophylaxis since at least 3 weeks, as per the indication of the referring hematologist;
- Ability to understand the nature of the study and voluntarily provide written informed consent patients whose responsiveness to the standard clopidogrel regimen was determined, based on clinical practice, using the VN-P2Y12 method.
Exclusion Criteria:
- Platelet count >1,000,000/μL on three separate determinations within the 2 months prior to enrollment;
- Need for anticoagulant therapy;
- Concomitant use of other antiplatelet agents;
- Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) (i.e > 3 days per week);
- Chronic corticosteroid therapy exceeding a daily dose equivalent to prednisone 5 mg
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
pharmacodynamic effectiveness of different clopidogrel dosing
Tidsramme: 15 days
|
To assess the pharmacodynamic effectiveness of an optimised clopidogrel dosing (75 mg bid) in ET patients with documented poor responsiveness to 75 mg od.
|
15 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
proportion of patients ET treated with standard-dose clopidogrel
Tidsramme: 15 days
|
To estimate the proportion of patients ET treated with standard-dose clopidogrel (75 mg once daily) who exhibit poor pharmacodynamic response to clopidogrel across
|
15 days
|
|
consistency over time of pharmacodynamic response
Tidsramme: 15 days
|
To assess the consistency over time of pharmacodynamic response in patients who are documented as good responders to clopidogrel 75 mg once daily with validated platelet function assays.
|
15 days
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Elena Rossi, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 27515
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .